GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Cirrhosis Liver/Oral Health Matters in Cirrhosis: JHEP Reports/ March 2026
28

Oral Health Matters in Cirrhosis: JHEP Reports/ March 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated March 1, 2026

Introduction:

Cirrhosis is increasingly recognised as a multisystem disease influenced by inflammation, microbiome alterations, and extrahepatic factors. Poor oral health, particularly periodontitis, contributes to systemic inflammation and bacterial translocation through the oral–gut–liver axis. However, whether improving oral hygiene through structured dental prophylactic services can modify the natural history of cirrhosis has remained largely unexplored in large real-world cohorts.

Problem Statement and Summary:

This large Veterans cohort study demonstrates that regular dental prophylaxis (≥1 visit/year) is independently associated with significantly lower rates of cirrhosis decompensation, including ascites and hepatic encephalopathy, as well as reduced hepatocellular carcinoma incidence and hospitalisations over 2 years. Importantly, this protective effect was specific to dental care and not merely a marker of healthcare engagement, as colonoscopy screening did not show similar benefits. The findings highlight a novel, modifiable and under-recognised factor in cirrhosis management.

Clinical Implication:

Routine dental care should be integrated into standard cirrhosis management, shifting focus toward holistic care and reinforcing the importance of the oral–liver axis in disease progression.

Related Q&A

29

Recompensation in Decompensated Cirrhosis: CGH/ April 2026

Introduction: Decompensated cirrhosis has traditionally been considered an irreversible stage of liver disease, associated with poor survival and frequent complications such as ascites, variceal bleeding, and hepatic encephalopathy....

30

Baclofen vs Acamprosate in Alcohol-Associated Cirrhosis: Alimentary Pharmacology & Therapeutics | March 2026

Introduction Management of alcohol use disorder in patients with cirrhosis remains a clinical challenge, where drug safety is as critical as efficacy. Acamprosate is generally preferred due to...

31

Early Portopulmonary Hypertension in Cirrhosis: Journal of Hepatology | February 2026

Introduction Portopulmonary hypertension represents a complex cardiopulmonary complication of cirrhosis that significantly impacts prognosis and transplant eligibility. Recent data from the PORTO-DETECT cohort have suggested that even early-stage...

32

Post-Banding Ulcer Bleeding After EBL: Alimentary Pharmacology & Therapeutics | March 2026

Introduction Endoscopic band ligation (EBL) remains the standard of care for managing esophageal varices, both in acute variceal bleeding and for prophylaxis. However, post-banding ulcer bleeding (PBUB) is...

33

Ammonia Measurement in Cirrhosis: Journal of Hepatology| March 2026

Introduction Ammonia has long been recognized as a central neurotoxin in the pathogenesis of hepatic encephalopathy, but its clinical use in cirrhosis has remained inconsistent because of major...

34

A-TANGO for ACLF: Journal of Hepatology | February 2026

Introduction Acute-on-chronic liver failure (ACLF) is a severe syndrome characterized by acute decompensation of cirrhosis, multiorgan failure, and high short-term mortality. The current EASL-CLIF criteria have been widely...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer